| TA Pharma Limited |
| Registered number: |
08632991 |
| Balance Sheet |
| as at 31 August 2025 |
|
| Notes |
|
|
2025 |
|
|
2024 |
| £ |
£ |
| Fixed assets |
| Tangible assets |
3 |
|
|
150 |
|
|
300 |
|
| Current assets |
| Cash at bank and in hand |
|
|
53,245 |
|
|
42,992 |
|
| Creditors: amounts falling due within one year |
4 |
|
(35,200) |
|
|
(6,373) |
|
| Net current assets |
|
|
|
18,045 |
|
|
36,619 |
|
| Total assets less current liabilities |
|
|
|
18,195 |
|
|
36,919 |
|
| Creditors: amounts falling due after more than one year |
5 |
|
|
(18,095) |
|
|
(21,827) |
|
|
|
| Net assets |
|
|
|
100 |
|
|
15,092 |
|
|
|
|
|
|
|
|
| Capital and reserves |
| Called up share capital |
|
|
|
100 |
|
|
100 |
| Profit and loss account |
|
|
|
- |
|
|
14,992 |
|
| Shareholders' funds |
|
|
|
100 |
|
|
15,092 |
|
|
|
|
|
|
|
|
| The directors are satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006. |
| The members have not required the company to obtain an audit in accordance with section 476 of the Act. |
| The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts. |
| The accounts have been prepared and delivered in accordance with the special provisions applicable to companies subject to the small companies regime. The profit and loss account has not been delivered to the Registrar of Companies. |
|
|
|
|
| Mohammed Hasan Noor |
| Director |
| Approved by the board on 14 March 2026 |
|
| TA Pharma Limited |
| Notes to the Accounts |
| for the year ended 31 August 2025 |
|
|
| 1 |
Accounting policies |
|
|
Basis of preparation |
|
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard). |
|
|
Turnover |
|
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. |
|
|
| 2 |
Employees |
2025 |
|
2024 |
| Number |
Number |
|
|
Average number of persons employed by the company |
2 |
|
1 |
|
|
|
|
|
|
|
|
|
|
| 3 |
Tangible fixed assets |
|
|
|
|
|
|
|
|
Plant and machinery etc |
| £ |
|
Cost |
|
At 1 September 2024 |
1,500 |
|
At 31 August 2025 |
1,500 |
|
|
|
|
|
|
|
|
|
|
Depreciation |
|
At 1 September 2024 |
1,200 |
|
Charge for the year |
150 |
|
At 31 August 2025 |
1,350 |
|
|
|
|
|
|
|
|
|
|
Net book value |
|
At 31 August 2025 |
150 |
|
At 31 August 2024 |
300 |
|
|
| 4 |
Creditors: amounts falling due within one year |
2025 |
|
2024 |
| £ |
£ |
|
|
Taxation and social security costs |
1,712 |
|
6,340 |
|
Other creditors |
33,488 |
|
33 |
|
|
|
|
|
|
35,200 |
|
6,373 |
|
|
|
|
|
|
|
|
|
|
| 5 |
Creditors: amounts falling due after one year |
2025 |
|
2024 |
| £ |
£ |
|
|
Bank loans |
3,095 |
|
6,827 |
|
Other creditors |
15,000 |
|
15,000 |
|
|
|
|
|
|
18,095 |
|
21,827 |
|
|
|
|
|
|
|
|
|
|
| 6 |
Other information |
|
|
TA Pharma Limited is a private company limited by shares and incorporated in England. Its registered office is: |
|
99 Osborn Road |
|
Birmingham |
|
B11 1TU |